ASO Author Reflections: Evaluation of Tumor Regression After Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma—How to Do It?

  • Flavio Roberto TakedaEmail author
  • Francisco Tustumi
  • Ivan Cecconello
ASO Author Reflections



Flavio Roberto Takeda, Francisco Tustumi, and Ivan Cecconello report no conflicts of interest.


  1. 1.
    Harada G, Bonadio RRDCC, de Araújo FCC, Victor CR, Sallum RAA, Junior UR, Cecconello I, Takeda FR, de Castria TB. Induction chemotherapy for locally advanced esophageal cancer. J Gastrointest Cancer. Epub 25 Jun 2019.
  2. 2.
    Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefPubMedGoogle Scholar
  3. 3.
    Takeda FR, Tustumi F, Obregon CA, Yogolare GG, Navarro YP, Segatelli V, et al. Prognostic value of tumor regression grade based on Ryan score in squamous cell carcinoma and adenocarcinoma of esophagus. Ann Surg Oncol.
  4. 4.
    Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014;260(5):807–13. (discussion 813-4).CrossRefPubMedGoogle Scholar
  5. 5.
    Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Gastroenterology, Digestive Surgery DivisionUniversity of São Paulo Medical SchoolSão PauloBrazil

Personalised recommendations